BETHESDA, Md.--(BUSINESS WIRE)--Cannabics Pharmaceuticals, Inc. (OTCQB: CNBX) announced today that the Company has made two key appointments to the Company's Advisory Board with the recent recruitment of Mr. Ika Abravanel as senior advisor in the field of operational and strategic planning, and Dr. Sigalit Ariely-Portnoy, as senior advisor in the field of regulation, validation and quality.
Both Mr. Abravanel and Dr. Ariely-Portnoy have substantial expertise, experience and knowledge relevant to the Company's mission and anticipated needs.
Mr. Ika Abravanel joined Teva Pharmaceutical Industries Ltd as its Corporate Vice President of Human Resources in 2007. During 2009, Mr. Abravanel was appointed as Teva’s Chief Integration Officer, and as such led the post-merger integration processes of Teva’s large acquisitions in recent years. In 2013 Mr. Abravanel was appointed as Group Executive Vice President of Teva Corporate in Israel and Global Community Alliances of Teva Pharmaceutical Industries Ltd. During that time he also served as Co-Chairman of the steering committee of PGT (Procter & Gamble - Teva joint venture in the field of OTC pharmaceuticals) on behalf of Teva. Mr. Abravanel holds a B.A. and an M.A. in Political Science from Haifa University and is a Graduate of the National Security College.
Dr. Sigalit Ariely-Portnoy has over 17 years’ experience in the pharmaceutical industry. During this time, she has managed pharmaceutical and chemical plants at Taro pharmaceutical industries Ltd as Operation Group Vice president and in Teva Pharmaceutical industries Ltd as Kfar-Saba OSD plant manager. Dr. Ariely-Portnoy managed Teva's largest plant worldwide (9 billion tablets per annum and more than $2B revenues). During her career, she led more than 50 inspections by the US FDA, EMEA, Israeli MOH, and others. Dr. Ariely-Portnoy spearheaded the construction of a 200,000 sq ft pharmaceutical plant, several chemical plants and bio-warehouses, as well as many significant plant expansions for manufacturers of semisolids, liquids and oral solid dosage forms. Between the years 2003-2006, Dr. Ariely-Portnoy was the president of the Israel chapter of the PDA (Parenteral Drug Association). In the last 4 and a half years, Dr. Ariely-Portnoy manages Gsap, a company which consults pharmaceutical, medical device and biotechnology companies in several major fields, including innovative product development, regulation, establishing quality systems and validation services. Dr. Ariely-Portnoy received her B.Sc., M.Sc., and D.Sc. from the Technion Institute of Technology in Haifa, Israel, in the fields of Chemical Engineering and Biomedical Engineering.
Dr. Zohar Koren, CEO of Cannabics Pharmaceuticals Inc, said, "Ika and Sigalit are both uniquely accomplished and highly qualified pharmaceutical industry veterans, who bring substantial skill sets and professional knowledge to our company at its current stage of rapid growth, scale up of manufacturing technologies, high volume market penetration and launch of clinical studies. With Ika's extensive experience in operational and strategic planning in the pharmaceutical and OTC markets, and Sigalit's long experience in designing GMP grade pharmaceutical manufacturing facilities, as well as in validation and regulatory processes, we anticipate that they will both play a prime role in our company’s advisory board and will make a significant contribution to the wide perspective of the company’s management team in the exciting and emerging field of advanced Cannabis based therapies and treatments. We are very proud and privileged to have them join us."
About Cannabics Pharmaceuticals, Inc.:
Cannabics Pharmaceuticals, Inc. is an emerging drug development company focused on the development and commercialization of advanced drugs, therapies, food supplements and administration routes based on the wide range of active ingredients found in diverse and unique strains of the Cannabis plant. Cannabics’ current flagship product is CANNABICS SR – an IP protected sustained release medical cannabis capsule designed specifically for cancer patients as a palliative care treatment. Cannabics’ proprietary SR technology provides 10-12 hours of steady state and beneficial therapeutic effects profile, and thus allows for a convenient oral, once-per-day dosing regimen of medical cannabis for patients. Cannabics is now preparing to launch its line of SR products in eligible states of the US and EU markets under existing medical cannabis regulatory pathways, while simultaneously preparing to launch a series of formal clinical studies in order to establish the unique medical benefits of its products for patients suffering from various indications.
Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on July 15th, 2014. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.
For more information, visit: http://www.cannabics.com